ArticleBMC nephrology2026
Effect of peritoneal dialysate on peritoneal fibrosis.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveLong-term peritoneal dialysis can lead to peritoneal fibrosis (PF), which impairs dialysis efficacy and adversely affects patients’ quality of life. This study aimed to investigate the effects of dialysate components on PF and the mechanisms involved.
methodsWe enrolled 30 peritoneal dialysis patients and analyzed the correlation between their blood glucose, blood pressure, blood calcium levels, and urine pH with PF severity. In addition, we evaluated the relationship between intraperitoneal dialysate dwell time and PF status. Human peritoneal mesothelial cells (HPMCs) were used as an in vitro model of PF and were treated with high glucose (HG), HCl induced low pH, and calcium chloride, respectively. The expression levels of α-smooth muscle actin (aSMA), fibronectin (Fn), collagen 1a1 (Col1a1), collagen 3a1 (Col3a1), and E-Cadherin (E-Ca) were measured to assess the mesothelial to mesenchymal transition (MMT) and fibrosis in HPMCs. Fibrosis-related signaling pathways were also examined to elucidate the underlying mechanisms.
resultsBlood glucose, blood pressure, blood calcium levels as well as intraperitoneal dialysate dwell time were positively correlated with PF in peritoneal dialysis patients, whereas urine pH was inversely correlated with PF score. Treatment of HPMCs with HG significantly increased the expression of aSMA (Acta2), Fn, Col1a1 (Col1a1), and Col3a1. By contrast, low pH and high Ca mainly induced pro-inflammatory cytokine expression in HPMCs. Additionally, we found high glucose primarily activated the TGFβ1 signaling pathway in HPMCs.
conclusionAmong the dialysate-related stressors examined in this study, high glucose most consistently promoted MMT-associated fibrogenic responses in mesothelial cells and was accompanied by activation of TGFβ1/Smad signaling. Low pH and elevated calcium primarily elicited inflammatory responses under the experimental conditions used. These findings are consistent with previous studies highlighting the importance of glucose-related stress in peritoneal remodeling and provide a comparative perspective on how different dialysate components may influence mesothelial cell responses.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.